Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2005 August;57(4) > Minerva Ginecologica 2005 August;57(4):461-6

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

ORIGINAL ARTICLES  PREGNANCY 

Minerva Ginecologica 2005 August;57(4):461-6

Copyright © 2005 EDIZIONI MINERVA MEDICA

language: English

Effectiveness and persistance of a topical treatment for cervical ectropion with deoxyribonucleic acid

Belfiore P., Costa E., De Cantis S., Vassallo R., Marino A.


PDF


Aim. The aim of this study was to estimate short and long term effectiveness of a topical treatment for cervical ectropion with 5 mg of deoxyribonucleic acid (DRNA).
Methods. A randomized case-control study was carried out. Two-hundred and twenty patients, colposcopically diagnosed with cervical ectropion, were consecutively enrolled and randomly divided into 2 groups: treated (group 1) and controls (group 2). The therapeutic plan consisted of DRNA 5 mg vaginal suppositories, administered for 15 days monthly; subsequently posology was reduced gradually. Both groups underwent a clinical and colposcopical follow-up on the 1st, 4th, 10th and 22nd months after the first examination. At the end of the study, the size of ectropion was considered a parameter of re-epithelialization and provided a criterion of treatment effectiveness. According to this protocol, subjects were defined improved, stable or worsened. Statistical analysis including Pearson x2 tests, Fisher's exact tests, Yate's corrected x2 and relative-risk (95% CI) was performed.
Results. Of the 220 enrolled patients, 140 completed the study protocol: 76 treated and 64 controls. Outcomes after treatment and follow-up consisted of: 74 (97.4%) improved in group 1, against 2 cases (3.1%) in group 2. High statistical significance was reported comparing outcome frequencies in the 2 groups (P<0.0001).
Conclusion. This study shows a significant reduction (P<0.0001) in cervical ectropion size between cases (topical treatment with DRNA 5 mg) and controls. A follow-up of 22 months confirmed the persistence and effectiveness of this medical approach.

top of page